![Barry L. Karger](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Barry L. Karger
Fondateur chez BioAnalytix, Inc.
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Alfonso Chang | M | - |
BioAnalytix, Inc.
![]() BioAnalytix, Inc. Information Technology ServicesTechnology Services BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA. | - |
Michael Chao | M | - |
BioAnalytix, Inc.
![]() BioAnalytix, Inc. Information Technology ServicesTechnology Services BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Kirtland Poss | M | - |
BioAnalytix, Inc.
![]() BioAnalytix, Inc. Information Technology ServicesTechnology Services BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA. | 9 ans |
Laszlo Takacs | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | 10 ans |
András Guttman | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | 10 ans |
Jean-Pierre Tirouflet | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | - |
Hubertus V. Sulkowski | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | - |
Wael Yared | M | 62 |
BioAnalytix, Inc.
![]() BioAnalytix, Inc. Information Technology ServicesTechnology Services BioAnalytix, Inc. develops and applies advanced analytic technologies. It offers advanced analytics, biologic therapeutics, mass spec, drug development and biopharma technologies. The company was founded by Barry L. Karger and Kirtland G. Poss in 2012 and is headquartered in Cambridge, MA. | 2 ans |
William Hancock | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | 14 ans |
Elisabeth Rocolle-Teyssier | F | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | - |
Sylvie le Gledic | M | - |
BioSystems International SAS
![]() BioSystems International SAS BiotechnologyHealth Technology Biosystems International is a biotechnology company engaged in protein biomarker R&D using a unique and proprietary monoclonal antibody based proteomics technology (mAb proteomics), leading to the development of: Novel blood-based diagnostics for cancer and chronic diseases through the use of its innovative mAb proteomics approach, BSI is poised to translate its discoveries into novel blood-based diagnostics products for the early detection of cancer, a number of chronic diseases, and cancer recurrence with its most advanced program in the area of lung cancer currently under development. | - |
Statistiques
Pays | Relations | % du total |
---|---|---|
France | 7 | 63,64% |
Etats-Unis | 4 | 36,36% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Barry L. Karger
- Réseau Personnel